aspirin has been researched along with Obesity, Morbid in 9 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin use is associated with increased rates of marginal ulceration after RYGB." | 9.41 | Aspirin Use as a Risk Factor for Marginal Ulceration in Roux-en-Y Gastric Bypass Patients: A Meta-Analysis of 24,770 Patients. ( Clapp, B; Dayyeh, BA; Ghanem, OM; Hassan, O; Portela, RC; Sharma, I; Spaniolas, K; Vahibe, A, 2023) |
| "Aspirin use is associated with increased rates of marginal ulceration after RYGB." | 5.41 | Aspirin Use as a Risk Factor for Marginal Ulceration in Roux-en-Y Gastric Bypass Patients: A Meta-Analysis of 24,770 Patients. ( Clapp, B; Dayyeh, BA; Ghanem, OM; Hassan, O; Portela, RC; Sharma, I; Spaniolas, K; Vahibe, A, 2023) |
| " The patient was subsequently found to have incomplete inhibition of platelet activity despite being on clopidogrel 150 mg and aspirin 81 mg daily and having a normal CYP-2C19 genotype, suggesting that suboptimal antiplatelet inhibition, secondary to morbid obesity, contributed to his in-stent thrombosis." | 3.79 | Obesity and intracranial in-stent thrombosis. ( Koch, S; Reyes-Iglesias, Y; Rose, DZ; Yavagal, DR, 2013) |
| " Patients who received low-molecular-weight heparin for prophylaxis against deep venous thrombosis had a longer time until the postoperative wound was dry than did those treated with aspirin and mechanical foot compression or those who received Coumadin (warfarin); this difference was significant on the fifth postoperative day (p = 0." | 3.74 | Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. ( DeWal, H; Di Cesare, PE; Patel, VP; Preston, C; Sehgal, B; Walsh, M, 2007) |
| "For SA, Tmax significantly decreased after RYGB, while both Cmax and AUC0-24 significantly increased." | 2.82 | The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study. ( Mitrov-Winkelmolen, L; Overdiek, HWPM; Swank, DJ; Touw, DJ; van Buul-Gast, MW; van Schaik, RHN, 2016) |
| "Laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery is a safe and effective procedure for patients with severe obesity." | 1.46 | Is Daily Low-Dose Aspirin Safe to Take Following Laparoscopic Roux-en-Y Gastric Bypass for Obesity Surgery? ( Amin, N; Anvari, M; Gmora, S; Hong, D; Kang, X; Tiboni, M, 2017) |
| "As the problem of morbid obesity has increased over the past several years in the United States, gastric bypass has become a viable option for many people seeking treatment." | 1.33 | Preventing vascular complications after gastric bypass. ( Heffline, MS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Portela, RC | 1 |
| Sharma, I | 1 |
| Vahibe, A | 1 |
| Hassan, O | 1 |
| Spaniolas, K | 1 |
| Dayyeh, BA | 1 |
| Clapp, B | 1 |
| Ghanem, OM | 1 |
| Won, KB | 1 |
| Shin, ES | 1 |
| Kang, J | 1 |
| Yang, HM | 1 |
| Park, KW | 1 |
| Han, KR | 1 |
| Moon, KW | 1 |
| Oh, SK | 1 |
| Kim, U | 1 |
| Rhee, MY | 1 |
| Kim, DI | 1 |
| Kim, SY | 1 |
| Lee, SY | 1 |
| Han, JK | 1 |
| Koo, BK | 1 |
| Kim, HS | 1 |
| Mojkowska, A | 1 |
| Gazdzinski, S | 1 |
| Fraczek, M | 1 |
| Wyleżoł, M | 1 |
| Mitrov-Winkelmolen, L | 1 |
| van Buul-Gast, MW | 1 |
| Swank, DJ | 1 |
| Overdiek, HWPM | 1 |
| van Schaik, RHN | 1 |
| Touw, DJ | 1 |
| Kang, X | 1 |
| Hong, D | 1 |
| Anvari, M | 1 |
| Tiboni, M | 1 |
| Amin, N | 1 |
| Gmora, S | 1 |
| Linares Vicente, JA | 1 |
| Pérez, JO | 1 |
| Lacasa, RC | 1 |
| Rose, DZ | 1 |
| Koch, S | 1 |
| Reyes-Iglesias, Y | 1 |
| Yavagal, DR | 1 |
| Heffline, MS | 1 |
| Patel, VP | 1 |
| Walsh, M | 1 |
| Sehgal, B | 1 |
| Preston, C | 1 |
| DeWal, H | 1 |
| Di Cesare, PE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729] | Phase 4 | 294 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for aspirin and Obesity, Morbid
| Article | Year |
|---|---|
Aspirin Use as a Risk Factor for Marginal Ulceration in Roux-en-Y Gastric Bypass Patients: A Meta-Analysis of 24,770 Patients.
Topics: Aspirin; Gastric Bypass; Humans; Obesity, Morbid; Retrospective Studies; Risk Factors; Ulcer | 2023 |
2 trials available for aspirin and Obesity, Morbid
| Article | Year |
|---|---|
Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents - Results From the HOST-EXAM Trial.
Topics: Aspirin; Body Mass Index; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Obesit | 2023 |
The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study.
Topics: Administration, Oral; Anti-Ulcer Agents; Area Under Curve; Aspirin; Female; Gastric Bypass; Humans; | 2016 |
6 other studies available for aspirin and Obesity, Morbid
| Article | Year |
|---|---|
Gastric Ulcer Hemorrhage - a Potential Life-Threatening Complication of Intragastric Balloon Treatment of Obesity.
Topics: Adult; Aspirin; Bariatric Surgery; Gastric Balloon; Gastrointestinal Hemorrhage; Helicobacter Infect | 2017 |
Is Daily Low-Dose Aspirin Safe to Take Following Laparoscopic Roux-en-Y Gastric Bypass for Obesity Surgery?
Topics: Adult; Aspirin; Female; Gastric Bypass; Humans; Laparoscopy; Male; Middle Aged; Obesity, Morbid; Pep | 2017 |
Long-term successful percutaneous coronary intervention in factor VII deficiency.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Diabetes M | 2012 |
Obesity and intracranial in-stent thrombosis.
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Aspirin; Body Mass Index; Brain Ischemia; C | 2013 |
Preventing vascular complications after gastric bypass.
Topics: Adult; Aged; Anticoagulants; Aspirin; Bandages; Clinical Protocols; Drug Monitoring; Early Ambulatio | 2006 |
Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Body Mass Index; Dra | 2007 |